Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Feasibility of a Venetoclax- Augmented Treosulfan-Based Reduced Intensity Conditioning Before Allogeneic Stem Cell Transplantation in AML, MDS/AML and Higher Risk MDS

NCT07214064 is registered in ClinicalTrials.gov with University Hospital Tuebingen as lead sponsor.

NCT NCT07214064
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07214064 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Feasibility of a Venetoclax- Augmented Treosulfan-Based Reduced Intensity Conditioning Before Allogeneic Stem Cell Transplantation in AML, MDS/AML and Higher Risk MDS
Lead sponsor
University Hospital Tuebingen
Phase
Phase 2
Overall status
Not yet recruiting
Start date
January 31, 2026
Completion date
December 31, 2027
Enrollment
27 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

aml (acute myeloid leukemia), mds (myelodysplastic syndrome), mds/aml